Addex Therapeutics Ltd (ADXN) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 49 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
Even with a 57/100 (D+) score, ADXN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.33) or 200D SMA ($5.80) invalidates the momentum regime and cuts Target Base ($2.92) toward Bear Floor ($2.28).
Addex Therapeutics Ltd (ADXN) slipped -1.01% to $2.93, trading at 5% of its 52-week range ($2.56 – $10.43). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel sm
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ADXN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ADXN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Addex Therapeutics Ltd (ADXN) ranks #259 by composite RQD confidence (57/100, grade D+) and #947 by equity capitalization ($5.0M). Within this direct 5-issuer industry benchmark cohort, ADXN leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. ADXN currently leads its immediate peer cohort in composite quantitative strength at 57/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ADXN
ACTIVE
Addex Therapeutics Ltd | D+ | 57/100 | — | — | — | -1.01% | $5.0M | Benchmark Subject |
| XBIO Xenetic Biosciences Inc. | D | 47/100 | — | — | -30.3% | +0.95% | $5.0M | /xbio-vs-adxn → |
| APUS Apimeds Pharmaceuticals US Inc. | D- | 43/100 | — | — | -6.2% | +4.56% | $5.0M | /apus-vs-adxn → |
| CANF Can-Fite Biopharma Ltd each representing two (2) | E | 31/100 | — | — | -35.0% | +0.61% | $5.0M | /canf-vs-adxn → |
| PULM Pulmatrix Inc. | D- | 36/100 | — | — | -35.0% | -5.67% | $5.2M | /pulm-vs-adxn → |
Addex Therapeutics Ltd (ADXN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $5.0M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, Addex Therapeutics Ltd (NASDAQ: ADXN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $2.93 (-1.01% 1D, market cap $5.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ADXN ranks #259 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADXN carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, XBIO (Xenetic Biosciences Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -30.3%, cap $5.0M) and APUS (Apimeds Pharmaceuticals US Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -6.2%, cap $5.0M). Among the 5-stock peer group, ADXN leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).
For Addex Therapeutics Ltd (ADXN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #259 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
ADXN last traded at $2.93 (-1.01% on volume of 2,366 shares), positioning the stock -12.01% below its 50-day simple moving average ($3.33) and -49.48% below its 200-day simple moving average ($5.80). Across its 52-week range of $2.56 to $10.43, ADXN sits at the 4.7% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.3% ($2.57 to $3.29).
Why ADXN Stock slipped -1.01% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.